Business Wire

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...
Psychology Today

The Power of the Group in Psychedelic-Assisted Therapy

In recent years, there has been much debate about the role of traditional therapy in psychedelic-assisted therapy. Some argue that the medicines are the primary agents of change, needing only minimal ...
Business Wire

Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy ...

PARIS--(BUSINESS WIRE)--Genethon, a pioneering gene therapy research organization created by AFM-Telethon, today presented positive results from the Phase 1/2 dose escalation part of an international ...